Literature DB >> 15208652

Brca1 inactivation induces p27(Kip1)-dependent cell cycle arrest and delayed development in the mouse mammary gland.

Andrew J Deans1, Kaylene J Simpson, Melanie K Trivett, Melissa A Brown, Grant A McArthur.   

Abstract

One common characteristic of breast cancers arising in carriers of the predisposition gene BRCA1 is a loss of expression of the CDK inhibitor p27(Kip1) (p27), suggesting that p27 interacts epistatically with BRCA1. To investigate this relationship, we examined expression of p27 in mice expressing a dominant negative allele of Brca1 (MMTV-trBr) in the mammary gland. While these mice rarely develop tumors, they showed a 50% increase in p27 protein and a delay in mammary gland development associated with reduced proliferation. In contrast, on a p27 heterozygote background, MMTV-trBrca1 mice showed an increase in S phase cells, and normal mammary development. p27 was the only protein in the cyclin-cyclin-dependent kinase network to show altered expression, suggesting that it may be a central mediator of cell cycle arrest in response to loss of function of BRCA1. Furthermore, in human mammary epithelial MCF7 cells expressing BRCA1-specific RNAi and in the BRCA1-deficient human tumor cell line HCC1937, p27 is elevated at the mRNA level compared to cells expressing wild-type BRCA1. We hypothesize that disruption of BRCA1 induces an increase in p27 that inhibits proliferation. Accordingly, reduction in p27 expression leads to enhancement of cellular proliferation in the absence of BRCA1.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15208652     DOI: 10.1038/sj.onc.1207805

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  6 in total

1.  Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033.

Authors:  Donna S Dorow; Carleen Cullinane; Nelly Conus; Peter Roselt; David Binns; Timothy J McCarthy; Grant A McArthur; Rodney J Hicks
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-02-01       Impact factor: 9.236

Review 2.  Role of the CDK inhibitor p27 (Kip1) in mammary development and carcinogenesis: insights from knockout mice.

Authors:  Elizabeth A Musgrove; Elizabeth A Davison; Christopher J Ormandy
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

3.  Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer.

Authors:  L P Jones; M T Tilli; S Assefnia; K Torre; E D Halama; A Parrish; E M Rosen; P A Furth
Journal:  Oncogene       Date:  2007-07-23       Impact factor: 9.867

4.  NFBD1/MDC1, 53BP1 and BRCA1 have both redundant and unique roles in the ATM pathway.

Authors:  Kathleen A Wilson; David F Stern
Journal:  Cell Cycle       Date:  2008-11-29       Impact factor: 4.534

5.  Physiological modulation of endogenous BRCA1 p220 abundance suppresses DNA damage during the cell cycle.

Authors:  Stoil D Dimitrov; David Lu; Nana Naetar; Yiduo Hu; Shailja Pathania; Chryssa Kanellopoulou; David M Livingston
Journal:  Genes Dev       Date:  2013-10-15       Impact factor: 11.361

6.  MiR-29b-1-5p is altered in BRCA1 mutant tumours and is a biomarker in basal-like breast cancer.

Authors:  Michael J G Milevskiy; Gurveen K Sandhu; Anna Wronski; Darren Korbie; Brooke L Brewster; Annette Shewan; Stacey L Edwards; Juliet D French; Melissa A Brown
Journal:  Oncotarget       Date:  2018-09-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.